AprilBio

AprilBio is pursuing a strategic revival for two drug candidates previously outlicensed to external partners. The biotech firm plans to announce its future development plans next week, focusing on repositioning these assets. The move reflects efforts to reassert control over its pipeline amid shifting industry dynamics.

Nov 2026TheBioNews article

AprilBio is preparing to launch a Phase 2b clinical trial for its atopic dermatitis drug **EVO301** in mid-next year. Early results show the SC-formulated treatment achieves an **EASI improvement rate comparable to Dupixent** after just two doses. The company continues to explore new drug development opportunities through technology exports, following setbacks in other projects like Lundbeck’s halted **APB-A1 TED** program.

Nov 2026EdailyNews article

Lundbeck is redirecting AprilBio’s experimental drug candidate **APB-A1** toward neurology applications, aiming to restart its development pipeline. The compound, originally out-licensed from South Korea’s AprilBio, had faced potential abandonment due to prior development risks. This strategic shift could reinvigorate its clinical potential and financial valuation for both companies.

Sep 2026ChosunBizNews article

AprilBio terminates its joint research agreement with Yuhan Corporation to focus exclusively on antibody-drug conjugates (ADC) and antibody-oriented conjugates (AOC) for cancer therapies. The move follows a 'selection and concentration' strategy aimed at adapting to evolving trends in global drug development. The collaboration, initiated in August 2022, is being discontinued early to prioritize AprilBio’s next-generation oncology platforms.

May 2026BigGo FinanceNews article